Establishment of a COVID-19 mRNA vaccine engineering transfer hub to scale up international producing

WHO and its partners are trying to get to expand the potential of minimal- and center-income countries (LMICs) to make COVID-19 vaccines and scale up producing to maximize world accessibility to these essential applications to bring the pandemic underneath regulate.

WHO will facilitate the institution of one particular (or much more, as appropriate) technological innovation transfer1 hub(s) that will  use a hub and spoke model (REF) to transfer a comprehensive engineering offer and give appropriate training to interested brands in LMICs. This initiative will to begin with prioritize the mRNA-vaccine know-how2 but could increase to other technologies in the foreseeable future.

The intention is for these hubs to empower the establishment of production system at an industrial or semi-industrial degree allowing schooling and provision of all needed conventional operating processes for manufacturing and excellent control. It is vital that the technology used is both free of mental home constraints in LMICs, or that these types of rights are built out there to the engineering hub and the potential recipients of the technological know-how by means of non-distinctive licenses to generate, export and distribute the COVID-19 vaccine in LMICs, including by the COVAX facility. Choice will be offered to applicants who have currently generated medical info in individuals, as such scientific data will add to accelerated acceptance of the vaccines in LMICs.

It is predicted that WHO will perform with funders and donors to mobilize monetary support to establish the hubs and, as they are getting recognized, to help the transfer of know-how to selected producers in LMICs, getting into consideration the require to build long-lasting vaccine creation capability in regions where by this is at present largely absent. This broader objective will make certain that all WHO regions will be able to develop vaccines as critical preparedness actions against long term infectious threats.

To assistance this action, we are looking for expressions of curiosity from:

  1. Tiny/middle-sized (public or non-public) manufacturers of clinical products (medications, vaccines or drug substances) ideally, but not solely, in LMICs, which could host a COVID-19 mRNA hub and:
    • Assemble the technological know-how up to excellent manufacturing procedures-grade pilot tons for clinical trials
    • Transfer the proper know-how and know-how to current or new brands in LMICs to help them to produce and create COVID-19 mRNA vaccines
  2. Proprietors (community or personal) of technology and/or mental residence legal rights. These may be educational institutions, pharmaceutical businesses, non-governmental corporations or any other entity eager to add these to a technologies transfer hub, underneath the auspices of WHO, to empower generation of mRNA-primarily based COVID-19 vaccines in LMICs.

For this preliminary expression of desire, entities ready to be regarded as a know-how transfer hub (as briefly described above underneath 1) or equipped to offer the important know-how, course of action teaching, and intellectual house legal rights (as briefly described previously mentioned less than 2), are invited to supply a transient summary of their capability, and their interest in collaborating in the institution of a COVID-19 vaccine technological innovation transfer hub to:

Martin Friede ([email protected]) and Raj Extensive ([email protected])

A phone for desire from suppliers in LMICs intrigued in obtaining the engineering developed by the technology transfer hub(s) will be issued by WHO in the coming months. Preference will be provided to makers of medicines, vaccines or lively pharmaceutical substances based in LMICs and capable of making clinical items on a huge scale beneath Fantastic Producing Procedures. Another vital aspect taken into thing to consider will be prospect for sustainability and practical experience with WHO Prequalification.


Know-how transfer hubs have been supported beforehand by WHO to enable the effective progress and transfer of procedures for adjuvant generation and for influenza vaccine output (ref).

The motives why WHO made a decision to advance right away on mRNA vaccines are as follows:

  • They have verified really efficacious in safeguarding in opposition to COVID-19, and defense is maintained to a significant diploma against variants
  • This know-how is extremely adaptable and makes it possible for fairly quick adaptation of the vaccine to variants, if wanted
  • They can be generated by suppliers of medicines and health-related energetic substances in addition to vaccines
  • Many specialized options are cost-free of Intellectual Assets Legal rights in numerous international locations of the earth.